Cempra, Inc. (CEMP)
-NasdaqGM 7.15 
0.02(0.28%) 10:21AM EDT - Nasdaq Real Time Price
| Prev Close: | 7.13 |
|---|
| Open: | 7.15 |
|---|
| Bid: | 7.13 x 200 |
|---|
| Ask: | 7.14 x 600 |
|---|
| 1y Target Est: | 11.25 |
|---|
| Beta: | 0.519 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 7.10 - 7.15 |
|---|
| 52wk Range: | 5.26 - 9.56 |
|---|
| Volume: | 10,920 |
|---|
| Avg Vol (3m): | 64,156 |
|---|
| Market Cap: | 178.06M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest volume increasesAP(Tue, Jun 18)
- Can Cempra Beat The Superbugs?at Seeking Alpha(Mon, Jun 17)
- Cempra falls as stock offering prices at discountAP(Fri, Jun 14)
- Groupon Soars on Upgrade, Cempra Craters on PO, and 3 More Hot Stocksat Wall St. Cheat Sheet(Fri, Jun 14)
- Cempra Prices Public Offering of Common StockPR Newswire(Fri, Jun 14)
- CEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and EEDGAR Online(Fri, Jun 14)
- Cempra sees 'clear direction' for approval for solithromycin after FDA meetingtheflyonthewall.com(Thu, Jun 13)
- Cempra Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)PR Newswire(Thu, Jun 13)
- Cempra Announces Proposed Public Offering of Common StockPR Newswire(Thu, Jun 13)
- CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, Jun 13)
- Gonorrhea Drug Resistance Recedes With New U.K. Approachat Bloomberg(Mon, Jun 10)
- CEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,EDGAR Online(Thu, Jun 6)
- CEMPRA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Mon, Jun 3)
- CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, May 30)
- Cempra announces notification of patent allowance for Taksta dose formulationtheflyonthewall.com(Thu, May 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.54 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.25 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to treat drug-resistant bacterial infections in the community and hospital.
View More